1-(1-phenyl-1H-pyrrol-2-yl)-1H-1,2,3-benzotriazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 1-(1-phenyl-1H-pyrrol-2-yl)-1H-1,2,3-benzotriazole
• 英文别名: 1-(1-Phenylpyrrol-2-yl)benzotriazole
• 化学式: C₁₆H₁₂N₄
• 分子量: 260.298
• InChiKey: HHLKQTSTFFHJAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  35.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  T406石油添加剂 、 2,5-二甲氧基-2,5-二氢呋喃 、 苯胺 在 溶剂黄146 作用下， 反应 24.0h， 以70%的产率得到5-(1H-1,2,3-benzotriazol-1-yl)-1-phenylpyrrolidin-2-one
  参考文献：
  名称：

  Preparation of 1,5-Disubstituted Pyrrolidin-2-ones

  摘要：

  1,5-Disubstituted pyrrolidin-2-ones 18a-g, 19a-h, and 20a-f were synthesized in good to excellent yields via the nucleophilic substitution of 5-(benzotriazol-1-yl)-1-substituted-pyrrolidin-2-ones 9 with allylsilanes, organozinc reagents, and phosphorus compounds. Compounds 9 and 5-(benzotriazol-2-yl)-1-substituted-pyrrolidin-2-one isomers 10 are readily prepared in total 70-84% yields from 2,5-dimethoxy-2,5-dihydrofuran (7), primary amines 8, and benzotriazole; 9 and 10 react identically with nucleophiles.

  DOI：

  10.1021/jo000219w

文献信息

• Novel benzotriazoles anti-inflammatory compounds
  申请人：Pfizer Inc.

  公开号：US20030078432A1

  公开（公告）日：2003-04-24

  The present invention relates to novel benzotriazoles of the formula I 1 wherein Het is an optionally substituted 5-membered heterocycle containing one to two heteroatoms selected from nitrogen, sulfur and oxygen wherein at least one of said heteroatoms atoms must be nitrogen; R 2 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; R 3 is selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl or other suitable substituents; s is an integer from 0-5; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.

  本发明涉及公式I的新型苯并三唑 其中Het是一个可选择取代的含有一个到两个来自氮、硫和氧的杂原子的5元杂环，其中至少一个杂原子必须是氮; R 2 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; R 3 选自由氢、(C 1 -C 6 )烷基或其他适当的取代基组成的群; s是0-5之间的整数; 用于它们的制备的中间体，含有它们的药物组合物以及它们的药用。本发明的化合物是MAP激酶，优选p38激酶的有效抑制剂。它们在治疗炎症、骨关节炎、类风湿性关节炎、癌症、中风或心脏病发作中的再灌注或缺血、自身免疫疾病和其他疾病中有用。
• US6664395B2
  申请人：——

  公开号：US6664395B2

  公开（公告）日：2003-12-16
• Preparation of 1,5-Disubstituted Pyrrolidin-2-ones
  作者：Alan R. Katritzky、Shamal Mehta、Hai-Ying He、Xilin Cui

  DOI：10.1021/jo000219w

  日期：2000.7.1

  1,5-Disubstituted pyrrolidin-2-ones 18a-g, 19a-h, and 20a-f were synthesized in good to excellent yields via the nucleophilic substitution of 5-(benzotriazol-1-yl)-1-substituted-pyrrolidin-2-ones 9 with allylsilanes, organozinc reagents, and phosphorus compounds. Compounds 9 and 5-(benzotriazol-2-yl)-1-substituted-pyrrolidin-2-one isomers 10 are readily prepared in total 70-84% yields from 2,5-dimethoxy-2,5-dihydrofuran (7), primary amines 8, and benzotriazole; 9 and 10 react identically with nucleophiles.